Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Semaglutide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Semaglutide as a study intervention. Browse Semaglutide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
308
Shown on this page
12
Local indexed summaries
102
Local recruiting
52

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Semaglutide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 1–12 of 308 matching trials for Semaglutide.
Live ClinicalTrials.gov results.

Top conditions

Obesity 37 Overweight 10 Diabetes Mellitus, Type 2 8 Type 2 Diabetes 7 Obesity & Overweight 5 Alcohol Use Disorder 3

Top sponsors

Novo Nordisk A/S 23 University of Colorado, Denver 5 Yale University 5 Mayo Clinic 4 The University of Texas Health Science Center, Houston 4 Vanderbilt University Medical Center 4

Top locations

Dallas, Texas 20 Houston, Texas 19 San Antonio, Texas 16 Philadelphia, Pennsylvania 13 Aurora, Colorado 11 Jacksonville, Florida 11

Live official records

Open in full search
Not yet recruiting Not applicable Interventional

Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia

NCT07878494
View directory record Official record
Conditions
Post-Bariatric Hypoglycemia
Interventions
Dietary Intervention, GLP-1 receptor agonist or Dual GIP/GLP-1 receptor agonist, Transoral Outlet Reduction (TORe)
Behavioral · Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Recruiting Phase 1 Interventional

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication

NCT07855133
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes
Interventions
Semaglutide, Zenagamtide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

NCT07845500
View directory record Official record
Conditions
Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
Interventions
Semaglutide, Berobenatide, Tirzepatide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

Semaglutide for Helping Opioid Recovery

NCT06639464
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Semaglutide, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Active, not recruiting Phase 3 Interventional

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT04822181
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
130
States / cities
Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Enrolling by invitation Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

NCT06897475
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY3457263, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Santa Ana, California • Ocala, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Recruiting Not applicable Interventional

MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease

NCT07478653
View directory record Official record
Conditions
Obesity, Dental Care for Children
Interventions
Dental Cleaning and Oral Hygiene Instruction (OHI), Oral Hygiene Instruction (OHI)
Procedure · Behavioral
Lead sponsor
Oelisoa Andriankaja
Other
Eligibility
12 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Coronado, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

NCT07668388
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
UBT251, UBT251 Placebo, Semaglutide, Semaglutide Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Fountain Valley, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

NCT05726227
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Escondido, California • New Haven, Connecticut • Columbus, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Active, not recruiting No phase listed Observational

Study of Patients Being Treated With Anti-obesity Medication

NCT06790160
View directory record Official record
Conditions
Obesity and Overweight
Interventions
Not listed
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 5:26 PM EDT

About this Semaglutide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Semaglutide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Semaglutide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Semaglutide.